

DAFTAR PUSTAKA

- Abraham, G., Kher, V., Saxena, S., Jayakumar, M., Chafekar, D., Pargaonkar, P., dkk., 2012. Sevelamer carbonate experience in Indian end stage renal disease patients. *Indian Journal of Nephrology*, **22**: 189–192.
- Ahlawat, R. dan Tiwari, P., 2016. Prevalence and Predictors of Medication Non-Adherence in Patients of Chronic Kidney Disease: Evidence from A Cross Sectional Study. *Journal of Pharmaceutical Care & Health Systems*, **03**: .
- Ahlström, T., Hagström, E., Larsson, A., Rudberg, C., Lind, L., dan Hellman, P., 2009. Correlation between plasma calcium, parathyroid hormone (PTH) and the metabolic syndrome (MetS) in a community-based cohort of men and women. *Clinical Endocrinology*, **71**: 673–678.
- Allredge, B.K., Corelli, R.L., Ernst, M.E., Guglielmo, B.J., Jacobson, P.A., Kradjan, W.A.*et al.*, 2013, *Koda Kimble and Young's Applied Therapeutics The Clinical Use of Drugs*, 10th ed., Lippincott Williams and Wilkins, USA, pp 662, 784-787.
- Al Wakeel, J.S., Mitwalli, A.H., Al Mohaya, S., Abu-Aisha, H., Tarif, N., Malik, G.H., dkk., 2002. Morbidity and mortality in ESRD patients on dialysis. *Saudi Journal of Kidney Diseases and Transplantation: An Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia*, **13**: 473–477.
- Arenas, M.D., Malek, T., Gil, M.T., Moledous, A., Alvarez-Ude, F., dan Reig-Ferrer, A., 2010. Challenge of phosphorus control in hemodialysis patients: a problem of adherence. *J Nephrol*, **23**: 525–34.

Bernard, L., Mendelssohn, D., Dunn, E., Hutchison, C., dan Grima, D.T., 2013. A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom. *Journal of Medical Economics*, **16**: 1–9.

Block, G.A., Klassen, P.S., Lazarus, J.M., Ofsthun, N., Lowrie, E.G., dan Chertow, G.M., 2004. Mineral Metabolism, Mortality, and Morbidity in Maintenance Hemodialysis. *Journal of the American Society of Nephrology*, **15**: 2208–2218.

CDC, 2014. 'National Chronic Kidney Disease Fact Sheet', . URL: https://www.cdc.gov/diabetes/pubs/pdf/kidney_factsheet.pdf.

Chertow, G.M., Burke, S.K., Dillon, M.A., Slatopolsky, E., dan Group, for the R.S., 1999. Long-Term Effects of Sevelamer Hydrochloride on the Calcium × Phosphate Product and Lipid Profile of Haemodialysis Patients. *Nephrology Dialysis Transplantation*, **14**: 2907–2914.

Chertow, G.M., Burke, S.K., Lazarus, J.M., Stenzel, K.H., Wombolt, D., Goldberg, D., dkk., 1997. Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. *American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation*, **29**: 66–71.

Chertow, G.M., Burke, S.K., Raggi, P., Group, T. to G.W., dan others, 2002. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. *Kidney international*, **62**: 245–252.

- Coladonato, J.A., 2005. Control of hyperphosphatemia among patients with ESRD. *Journal of the American Society of Nephrology: JASN*, **16 Suppl 2**: S107-114.
- Davies, E.W., Matza, L.S., Worth, G., Feeny, D.H., Kostelec, J., Soroka, S., dkk., 2015. Health state utilities associated with major clinical events in the context of secondary hyperparathyroidism and chronic kidney disease requiring dialysis. *Health and Quality of Life Outcomes*, **13**: 90.
- Delmez, J., Block, G., Robertson, J., Chasan-Taber, S., Blair, A., Dillon, M., dkk., 2007. A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. *Clinical Nephrology*, **68**: 386–391.
- Di Iorio, B., Molony, D., Bell, C., Cucciniello, E., Bellizzi, V., Russo, D., dkk., 2013. Sevelamer Versus Calcium Carbonate in Incident Hemodialysis Patients: Results of an Open-Label 24-Month Randomized Clinical Trial. *American Journal of Kidney Diseases*, **62**: 771–778.
- Duggal, A., Hanus, M., Zhorov, E., Dagher, R., Plone, M.A., Goldberg, J., dkk., 2006. Novel dosage forms and regimens for sevelamer-based phosphate binders. *Journal of Renal Nutrition: The Official Journal of the Council on Renal Nutrition of the National Kidney Foundation*, **16**: 248–252.
- Emmett, M., 2004. A comparison of clinically useful phosphorus binders for patients with chronic kidney failure. *Kidney International*, **66**: S25–S32.
- Fan, S., Ross, C., Mitra, S., Kalra, P., Heaton, J., Hunter, J., dkk., 2009. A randomized, crossover design study of sevelamer carbonate powder and

sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis. *Nephrology Dialysis Transplantation*, **24**: 3794–3799.

Ferreira, A., Frazão, J.M., Monier-Faugere, M.-C., Gil, C., Galvao, J., Oliveira, C., dkk., 2008. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. *Journal of the American Society of Nephrology: JASN*, **19**: 405–412.

Firdous, S.S., Siddiqua, A., Navaneetha, K., Srujana, P., dan Kumar, S.M., 2014. Assessment of Risk Factor and Medication Adherence of Chronic Kidney Disease Patients in a Tertiary Care Teaching Hospital. *International Journal of Allied Medical Sciences and Clinical Research*, **2**: 395–400.

Ghimire, S., Castelino, R.L., Lioufas, N.M., Peterson, G.M., dan Zaidi, S.T.R., 2015. Nonadherence to Medication Therapy in Haemodialysis Patients: A Systematic Review. *PLOS ONE*, **10**: e0144119.

Goldberg, I. dan Krause, I., 2016. The Role of Gender in Chronic Kidney Disease. *EMJ*, **1**: 58–64.

Hallan, S.I., Matsushita, K., Sang, Y., Mahmoodi, B.K., Black, C., Ishani, A., dkk., 2012. Age and the Association of Kidney Measures with Mortality and End-Stage Renal Disease. *JAMA: the journal of the American Medical Association*, **308**: 2349–2360.

Hanus, M., Zhorov, E., Brommage, D., Plone, M., dan Holmes-Farley, S.R., 2012. Assessment of phosphate binding by sevelamer carbonate powder for oral suspension mixed in foods. *Nephrology Nursing Journal*, **39**: 239.

- Hruska, K.A. dan Mathew, S., 2011. The Roles of the Skeleton and Phosphorus in the CKD Mineral Bone Disorder. *Advances in chronic kidney disease*, **18**: 98–104.
- Hruska, K.A., Mathew, S., Lund, R., Qiu, P., dan Pratt, R., 2008. Hyperphosphatemia of chronic kidney disease. *Kidney International*, **74**: 148–157.
- Hudson, M.S., 2008. Chronic Kidney Disease: Management of Complications, dalam: *Pharmacotherapy A Pathophysiologic Approach*. McGraw Hill, New York.
- Hutchison, A.J., 2009. Oral phosphate binders. *Kidney International*, **75**: 906–914.
- Isakova, T., Gutiérrez, O.M., Chang, Y., Shah, A., Tamez, H., Smith, K., dkk., 2009. Phosphorus Binders and Survival on Hemodialysis. *Journal of the American Society of Nephrology : JASN*, **20**: 388–396.
- Joy, M.S., Khirsagar, A., dan Franceschini, G.C., 2008. Chronic Kidney Disease: Progression-Modifying Therapies, dalam: *Pharmacotherapy A Pathophysiology Approach*. Mc Graw Hill, New York, hal. 745–750.
- Jungers, P., Chauveau, P., Descamps-Latscha, B., Labrunie, M., Giraud, E., Man, N.K., dkk., 1996. Age and gender-related incidence of chronic renal failure in a French urban area: a prospective epidemiologic study. *Nephrology Dialysis Transplantation*, **11**: 1542–1546.
- Jurkovitz, C.T., Qiu, Y., Wang, C., Gilbertson, D.T., dan Brown, W.W., 2008. The Kidney Early Evaluation Program (KEEP): program design and

demographic characteristics of the population. *American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation*, **51**: S3-12.

Kalantar-Zadeh, K., Gutekunst, L., Mehrotra, R., Kovesdy, C.P., Bross, R., Shinaberger, C.S., dkk., 2010. Understanding Sources of Dietary Phosphorus in the Treatment of Patients with Chronic Kidney Disease. *Clinical Journal of the American Society of Nephrology*, **5**: 519–530.

KDIGO, 2012. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney International*, **2**: .

Kementerian Kesehata RI, 2013. *Riset Kesehatan Dasar (RISKESDAS) 2013*. Kementrian Kesehatan RI, Jakarta.

Kucirka, L.M., Grams, M.E., Lessler, J., Hall, E.C., James, N., Massie, A.B., dkk., 2011. Association of Race and Age With Survival Among Patients Undergoing Dialysis. *JAMA*, **306**: 620–626.

Lam, W.Y., Fresco, P., Lam, W.Y., dan Fresco, P., 2015. Medication Adherence Measures: An Overview, Medication Adherence Measures: An Overview. *BioMed Research International, BioMed Research International*, **2015**: e217047.

Lemeshow, S., Hosmer, D.W., Klar, J., dan Lwanga, S.K., 1990. *Adequacy of Sample Size in Health Studies*. John Wiley & Sons Ltd, Inggris.

Levin, A., Singer, J., Thompson, C.R., Ross, H., dan Lewis, M., 1996. Prevalent left ventricular hypertrophy in the predialysis population: identifying

opportunities for intervention. *American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation*, **27**: 347–354.

Li, Z.-Y., Xu, G.-B., Xia, T.-A., dan Wang, H.-Y., 2006. Prevalence of chronic kidney disease in a middle and old-aged population of Beijing. *Clinica Chimica Acta*, **366**: 209–215.

Manns, B., Stevens, L., Miskulin, D., Owen, W.F., Winkelmayer, W.C., dan Tonelli, M., 2004. A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States. *Kidney International*, **66**: 1239–1247.

Mason, D.L. dan Assimon, M.L., 2013. Chronic Kidney Disease, dalam: *Applied Therapeutics: The Clinical Use of Drugs*. Wolter Kluwer/Lippincott Williams&Wilkins, Philadelphia.

Michels, T.C. dan Kelly, K.M., 2013. Parathyroid Disorders. *American Family Physician*, **88**: 249–257.

Morisky, D.E., Ang, A., Wood, M.K., dan Ward, H.J., 2008. Predictive Validity of A Medication Adherence Measure in an Outpatient Setting. *J Clin Hypertens*, **10**: 348–354.

Nadin, C., 2005. Sevelamer as a phosphate binder in adult hemodialysis patients: an evidence-based review of its therapeutic value. *Core Evidence*, **1**: 43–63.

National Kidney Foundation, 2002. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

*American Journal of Kidney Diseases: The Official Journal of the
National Kidney Foundation*, **39**: S1-266.

National Kidney Foundation, 2003. K/DOQI clinical practice guidelines for bone
metabolism and disease in chronic kidney disease. *American Journal of
Kidney Diseases: The Official Journal of the National Kidney Foundation*,
42: S1-201.

National Kidney Foundation, 2015. 'Dialysis', *National Kidney Foundation*. URL:
<https://www.kidney.org/atoz/content/dialysisinfo>.

NHS, 2008. *Diagnosis and Management of Chronic Kidney Disease a National
Clinical Guideline*. Scottish Intercollegiate Network, Scotland.

Octawati, I., 2005. 'Profil Kadar Hormon Paratiroid, Kalsium dan Fosfat pada
Pasien Gagal Ginjal Kronik yang Dilakukan Tindakan Hemodialisis di
Rumah Sakit Dr. Sardjito Yogyakarta', . Universitas Gadjah Mada,
Yogyakarta.

Ossareh, S., 2014. Clinical and economic aspects of sevelamer therapy in end-
stage renal disease patients. *International Journal of Nephrology and
Renovascular Disease*, **7**: 161–168.

Ossareh, S., Tabrizian, S., Zebarjadi, M., dan Joodat, R.S., 2014. Prevalence of
depression in maintenance hemodialysis patients and its correlation with
adherence to medications. *Iranian journal of kidney diseases*, **8**: 467.

Palmer, S.C., Gardner, S., Tonelli, M., Mavridis, D., Johnson, D.W., Craig, J.C.,
dkk., 2016. Phosphate-Binding Agents in Adults With CKD: A Network

Meta-analysis of Randomized Trials. *American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation*, .

Palmer, S.C., Hayen, A., Macaskill, P., Pellegrini, F., Craig, J.C., Elder, G.J., dkk., 2011. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. *JAMA*, **305**: 1119–1127.

PERNEFRI, 2012. '5th Report of Indonesian Renal Registry', . URL: <http://www.indonesianrenalregistry.org/data/5th%20Annual%20Report%20Of%20IRR%202012.pdf>.

Plakas, S., Mastrogiannis, D., Mantzorou, M., Adamakidou, T., Fouka, G., Bouziou, A., dkk., 2016. Validation of the 8-Item Morisky Medication Adherence Scale in Chronically Ill Ambulatory Patients in Rural Greece. *Open Journal of Nursing*, **06**: 158–169.

Prakash, S. dan O'Hare, A.M., 2009. Interaction of Aging and CKD. *Seminars in nephrology*, **29**: 497–503.

Price, S.A. dan Wilson, L.M., 2006. *Patofisiologi Konsep Klinis Proses-Proses Penyakit*, 6th ed. Penerbit Buku Kedokteran EGC, Jakarta.

Prodjosudjadi, W. dan Suhardjono, A., 2009. End-stage renal disease in Indonesia: treatment development. *Ethnicity & Disease*, **19**: S1-33–6.

Ribeiro, S., Ramos, A., Brandão, A., Rebelo, J.R., Guerra, A., Resina, C., dkk., 1998. Cardiac valve calcification in haemodialysis patients: role of calcium-phosphate metabolism. *Nephrology, Dialysis, Transplantation*:

Official Publication of the European Dialysis and Transplant Association

- European Renal Association, 13: 2037–2040.

Ruggeri, M., Bellasi, A., Cipriani, F., Molony, D., Bell, C., Russo, D., dkk., 2015.

Sevelamer is cost effective versus calcium carbonate for the first-line treatment of hyperphosphatemia in new patients to hemodialysis: a patient-level economic evaluation of the INDEPENDENT-HD study.

Journal of Nephrology, 28: 593–602.

Savica, V., Santoro, D., Monardo, P., Mallamace, A., dan Bellinghieri, G., 2008a.

Sevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis. *Ther Clin Risk Manag, 4: 821.*

Savica, V., Santoro, D., Monardo, P., Mallamace, A., dan Bellinghieri, G., 2008b.

Sevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis. *Ther Clin Risk Manag, 4: 821.*

Setiani Agus, L., Effendi, I., dan Abdillah, S., 2014. Influence of the use of phosphate binders on serum levels of calcium phosphate in patients with chronic kidney disease undergoing hemodialysis: A retrospective and prospective study. *Saudi pharmaceutical journal: SPJ: the official publication of the Saudi Pharmaceutical Society, 22: 333–337.*

Shaman, A.M. dan Kowalski, S.R., 2016. Hyperphosphatemia Management in

Patients with Chronic Kidney Disease. *Saudi Pharmaceutical Journal, 24: 494–505.*

Silbiger, S. dan Neugarten, J., 2008. Gender and human chronic renal disease.

Gender Medicine, **5**: S3–S10.

Silbiger, S.R. dan Neugarten, J., 1995. The impact of gender on the progression of chronic renal disease. *American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation*, **25**: 515–533.

Simoni, J.M., Kurth, A.E., Pearson, C.R., Pantalone, D.W., Merrill, J.O., dan Frick, P.A., 2006. Self-Report Measures of Antiretroviral Therapy Adherence: A Review with Recommendations for HIV Research and Clinical Management. *AIDS and behavior*, **10**: 227–245.

Singh, N.P., Rathi, B.M., dan Panwar, B., 2008. Hyperphosphataemia of chronic kidney disease: management and Emerging Trends. *Journal, Indian Academy of Clinical Medicine*, **9**: 291.

Smith, J.M.S., 2003. Chronic Renal Failure, dalam: *Clinical Pharmacy and Therapeutics*. Churchill Livingstone, London.

Sukandar, E.Y., Andrajati, R., Adnyana, I.K., Setiadi, A.P., dan Kusnandar, 2011. Gagal Ginjal Kronik, dalam: *ISO Farmakoterapi 2*. Ikatan Apoteker Indonesia, Jakarta, hal. 345–347.

Syaiful, H.Q., Oenzil, F., dan Afriant, R., 2014. Hubungan umur dan lamanya hemodialisis dengan status gizi pada penderita Penyakit Ginjal Kronik yang menjalani hemodialisis di RS. Dr. M. Djamil Padang. *Jurnal Kesehatan Andalas*, **3**: .

- Taylor, M.J., Elgazzar, H.A., Chaplin, S., Goldsmith, D., dan Molony, D.A.,
2008. An economic evaluation of sevelamer in patients new to dialysis.
Current Medical Research and Opinion, **24**: 601–608.
- Thomas, R., Kanso, A., dan Sedor, J.R., 2008. Chronic Kidney Disease and Its
Complications. *Primary care*, **35**: 329–vii.
- Umeukeje, E.M., Merighi, J.R., Browne, T., Carlsson, J.N., Umanath, K., Lewis,
J.B., dkk., 2015. Self-motivation is associated with phosphorus control in
End-Stage Renal Disease. *Journal of renal nutrition : the official journal
of the Council on Renal Nutrition of the National Kidney Foundation*, **25**:
433–439.
- United States Renal Data System, 2015. 'USRDS annual data report:
Epidemiology of kidney disease in the United States', . URL: [http://
www.usrds.org/adr.aspx](http://www.usrds.org/adr.aspx).
- Wilson, L.M., 2006. Penyakit Ginjal Stadium akhir: Sindrom Uremik, dalam:
Patofisiologi Konsep Klinis Proses-Proses Penyakit. Penerbit Buku
Kedokteran EGC, Jakarta, hal. 958–960.
- Wouters, O.J., O'Donoghue, D.J., Ritchie, J., Kanavos, P.G., dan Narva, A.S.,
2015. Early chronic kidney disease: diagnosis, management and models of
care. *Nature reviews. Nephrology*, **11**: 491–502.